Cellect Biotechnology Ltd is a biotechnology business based in the US. Cellect Biotechnology shares (APOP) are listed on the NASDAQ and all prices are listed in US Dollars. Cellect Biotechnology employs 12 staff and has a market cap (total outstanding shares value) of 0.00.
How to buy shares in Cellect Biotechnology
- Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – APOP – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
What's in this guide?
Cellect Biotechnology stock price (NASDAQ: APOP)Use our graph to track the performance of APOP stocks over time.
Cellect Biotechnology shares at a glance
|Latest market close||$16.29|
|52-week range||$6.60 - $35.52|
|50-day moving average||$21.04|
|200-day moving average||$15.29|
|Wall St. target price||$12.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.85|
Buy Cellect Biotechnology shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Cellect Biotechnology stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Cellect Biotechnology price performance over time
|1 week (2021-10-08)||-7.13%|
|1 month (2021-09-15)||164.02%|
|3 months (2021-07-15)||295.39%|
|6 months (2021-04-15)||546.43%|
|1 year (2020-10-15)||633.78%|
|2 years (2019-10-15)||3,618.33%|
|3 years (2018-10-15)||219.41%|
|5 years (2016-10-14)||286.02%|
Cellect Biotechnology financials
|Gross profit TTM||$0|
|Return on assets TTM||-47.79%|
|Return on equity TTM||-120.42%|
|Market capitalisation||$17.2 million|
TTM: trailing 12 months
Shorting Cellect Biotechnology shares
There are currently 288,114 Cellect Biotechnology shares held short by investors – that's known as Cellect Biotechnology's "short interest". This figure is 88.7% up from 152,705 last month.
There are a few different ways that this level of interest in shorting Cellect Biotechnology shares can be evaluated.
Cellect Biotechnology's "short interest ratio" (SIR)
Cellect Biotechnology's "short interest ratio" (SIR) is the quantity of Cellect Biotechnology shares currently shorted divided by the average quantity of Cellect Biotechnology shares traded daily (recently around 4.8 million). Cellect Biotechnology's SIR currently stands at 0.06. In other words for every 100,000 Cellect Biotechnology shares traded daily on the market, roughly 60 shares are currently held short.
However Cellect Biotechnology's short interest can also be evaluated against the total number of Cellect Biotechnology shares, or, against the total number of tradable Cellect Biotechnology shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Cellect Biotechnology's short interest could be expressed as 0.07% of the outstanding shares (for every 100,000 Cellect Biotechnology shares in existence, roughly 70 shares are currently held short) or 0.0764% of the tradable shares (for every 100,000 tradable Cellect Biotechnology shares, roughly 76 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Cellect Biotechnology.
Find out more about how you can short Cellect Biotechnology stock.
Cellect Biotechnology share dividends
We're not expecting Cellect Biotechnology to pay a dividend over the next 12 months.
Have Cellect Biotechnology's shares ever split?
Cellect Biotechnology's shares were split on a 1:5 basis on 22 October 2019. So if you had owned 5 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Cellect Biotechnology shares – just the quantity. However, indirectly, the new 400% higher share price could have impacted the market appetite for Cellect Biotechnology shares which in turn could have impacted Cellect Biotechnology's share price.
Cellect Biotechnology share price volatility
Over the last 12 months, Cellect Biotechnology's shares have ranged in value from as little as $6.598 up to $35.52. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cellect Biotechnology's is 1.8767. This would suggest that Cellect Biotechnology's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Cellect Biotechnology overview
Cellect Biotechnology Ltd. , a biotechnology company, engages in developing ApoGraft, a technology platform that functionally selects stem cells to enhance the safety of regenerative medicine and stem cell therapies in Israel. The company develops ApoTainer, a kit for hematopoietic stem cell transplantation procedures. It has collaborations with the denovoMATRIX group of the Technische Universität Dresden to conduct examinations into the tentative synergy between ApoGraft and denovoMAtrix technology for the purpose of evaluating collaborative development of products for regenerative medicine; Cell2in Inc. to conduct scientific evaluations combining ApoGraft with Cell2in's identification technology FreSHtracer, which monitors stem cell quality by utilizing a fluorescent dye to characterize their oxidative stress state; and XNK therapeutics to focus on the development of cell-based therapeutics from NK cells. The company was formerly known as Cellect Biomed Ltd. and changed its name to Cellect Biotechnology Ltd.
Cellect Biotechnology in the news
5 Short Squeeze Candidates To Watch: Bit Digital, Camber Energy Rejoin The List
Short Squeeze Stocks: BMRA, PROG and 3 Other Stocks Experts Think Are Ready to Pop
5 Short Squeeze Candidates To Watch: Aterian, Marin On List Again, Plus 3 New Small-Cap Medical Plays
Frequently asked questionsWhat percentage of Cellect Biotechnology is owned by insiders or institutions?
Currently 3.647% of Cellect Biotechnology shares are held by insiders and 12.227% by institutions. How many people work for Cellect Biotechnology?
Latest data suggests 12 work at Cellect Biotechnology. When does the fiscal year end for Cellect Biotechnology?
Cellect Biotechnology's fiscal year ends in December. Where is Cellect Biotechnology based?
Cellect Biotechnology's address is: 23 Hata?as Street, Kfar Saba, Israel, 44425 What is Cellect Biotechnology's ISIN number?
Cellect Biotechnology's international securities identification number is: US15116C2017 What is Cellect Biotechnology's CUSIP number?
Cellect Biotechnology's Committee on Uniform Securities Identification Procedures number is: 000241018
More guides on Finder
How to buy Aura Biosciences (AURA) stock when it goes public
Everything we know about the Aura Biosciences IPO, plus information on how to buy in.
How to buy Claros Mortgage Trust (CMTG) stock when it goes public
Everything we know about the Claros Mortgage Trust IPO, plus information on how to buy in.
How to buy Evotec SE (EVO) stock when it goes public
Everything we know about the Evotec SE IPO, plus information on how to buy in.
How to buy Delimobil Holding SA (DMOB) stock when it goes public
Everything we know about the Delimobil Holding SA IPO, plus information on how to buy in.
How to buy Blue Water Vaccines (BWV) stock when it goes public
Everything we know about the Blue Water Vaccines IPO, plus information on how to buy in.
How to buy Sonendo (SONX) stock when it goes public
Everything we know about the Sonendo IPO, plus information on how to buy in.
How to buy FlexEnergy Green Solutions (FLXE) stock when it goes public
Everything we know about the FlexEnergy Green Solutions IPO, plus information on how to buy in.
How to buy Stran & Company (STRN) stock when it goes public
Everything we know about the Stran & Company IPO, plus information on how to buy in.
How to buy Kidpik Corp (PIK) stock when it goes public
Everything we know about the Kidpik Corp IPO, plus information on how to buy in.
How to buy Nuvectis Pharma (NVCT) stock when it goes public
Everything we know about the Nuvectis Pharma IPO, plus information on how to buy in.
Ask an Expert